Related references
Note: Only part of the references are listed.TGF-β Promotes Heterogeneity and Drug Resistance in Squamous Cell Carcinoma
Naoki Oshimori et al.
CELL (2015)
Targeting the TGFβ pathway for cancer therapy
Cindy Neuzillet et al.
PHARMACOLOGY & THERAPEUTICS (2015)
microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition
Aditya Parikh et al.
NATURE COMMUNICATIONS (2014)
New Strategies in the Treatment of Ovarian Cancer: Current Clinical Perspectives and Future Potential
Susana Banerjee et al.
CLINICAL CANCER RESEARCH (2013)
Targeting IGF-1 signaling pathways in gynecologic malignancies
Ilan Bruchim et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2013)
TGF-β-induced expression of IGFBP-3 regulates IGF1R signaling in human osteosarcoma cells
Lynette J. Schedlich et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2013)
Targeting the Insulin Growth Factor and the Vascular Endothelial Growth Factor Pathways in Ovarian Cancer
Minghai Shao et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Targeting the TGFβ signalling pathway in disease
Rosemary J. Akhurst et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Expression of the IGF Axis Is Decreased in Local Prostate Cancer but Enhanced after Benign Prostate Epithelial Differentiation and TGF-β Treatment
Petra Massoner et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Rethinking ovarian cancer: recommendations for improving outcomes
Sebastian Vaughan et al.
NATURE REVIEWS CANCER (2011)
The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory
Robert J. Kurman et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)
TGF-β Receptor Inhibitors Target the CD44high/Id1high Glioma-Initiating Cell Population in Human Glioblastoma
Judit Anido et al.
CANCER CELL (2010)
Integrated genomics of chemotherapy resistant ovarian cancer: A role for extracellular matrix, TGFbeta and regulating microRNAs
Jozien Helleman et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2010)
The ovary: basic biology and clinical implications
JoAnne S. Richards et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer
Elizabeth Buck et al.
MOLECULAR CANCER THERAPEUTICS (2010)
The genesis and evolution of high-grade serous ovarian cancer
David D. L. Bowtell
NATURE REVIEWS CANCER (2010)
TGFβ signalling: a complex web in cancer progression
Hiroaki Ikushima et al.
NATURE REVIEWS CANCER (2010)
The biology of ovarian cancer: new opportunities for translation
Robert C. Bast et al.
NATURE REVIEWS CANCER (2009)
The TGF beta pathway as a therapeutic target in cancer
Joan Seoane
CLINICAL & TRANSLATIONAL ONCOLOGY (2008)
New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact
Keren Levanon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Redundant Roles of SMAD2 and SMAD3 in Ovarian Granulosa Cells In Vivo
Qinglei Li et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis
Davide Melisi et al.
MOLECULAR CANCER THERAPEUTICS (2008)
High TGFβ-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene
Alejandra Bruna et al.
CANCER CELL (2007)
The logic of TGFβ signaling
Joan Massague et al.
FEBS LETTERS (2006)
Mechanisms of TGF-β signaling from cell membrane to the nucleus
YG Shi et al.
CELL (2003)
Share Paper
